Meister Keith A. sold $148.2M of ILMN (indirect holdings)

Meister Keith A. sold 741,127 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $199.91 ($196.74–$203.28, $148.16M total) across 14 trades over 2026-08-04 to 2026-08-05.

Original reporting
SEC EDGAR · Meister Keith A.
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ILMN
Neutral
medium confidence
Mentioned
$ILMN
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ILMNNeutralLow
01

Why it matters

A director’s large open-market sale can influence short-term sentiment and options positioning, but the filing does not include any new company-specific performance, guidance, or regulatory developments.

02

Market read

Traders may monitor for follow-on selling or interpret the transaction as a sentiment signal, but there is no new fundamental catalyst in the text.

03

What to watch

Indirect holdings and multi-trade execution can reflect pre-planned personal tax or estate liquidity needs rather than a view on ILMN fundamentals.

Relevance 8/10Novelty 5/10Timing: filed Aug 6, covering sales on Aug 4-5

Background

This is an SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

$ILMNNeutralMedium confidence
Context

Illumina director Keith A. Meister sold $148.2M of ILMN via 14 open-market trades at $196.74 to $203.28, indirect holdings.

Expected impact

Likely limited, short-lived negative drift around insider-selling headlines; no direct guidance or business update is provided.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a sizable notional, which can affect sentiment. However, the article contains no new operational, financial, or regulatory facts that would reprice fundamentals.

Market effects

Could marginally affect sentiment toward genomics tools/diagnostics peers if traders extrapolate insider risk, but no sector-wide catalyst is disclosed.

Primarily US large-cap sentiment; no cross-region linkage is provided.

No global macro or international transaction details are included.

Counterpoint

The sale may be routine liquidity or diversification, and the absence of a stated 10b5-1 plan does not necessarily imply negative company outlook.

Key entities

  • Illumina, Inc.

    Subject of the Form 4 insider sale; director Keith A. Meister reduced indirect holdings.

  • Meister Keith A.

    Director who sold 741,127 shares across 14 trades for about $148.16M.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ILMNMed

Illumina selected to help bring precision medicine into everyday healthcare in Singapore

Illumina (ILMN) was selected for the SG-INSIGHT study, part of Singapore's National Precision Medicine program, to provide whole-genome sequencing for 450,000 residents. The study aims to integrate genomic data with healthcare to tailor treatments. Illumina will operate through its local facility, complying with Singapore's regulations. This follows their support in the previous phase of the program.

$ILMNHighAI 9/10

What Sent Illumina Stock Lower?

Illumina (ILMN) stock dropped 18.6% on October 30, 2026, despite beating earnings estimates and raising its full-year revenue outlook. The decline followed a mixed Q3 report where revenue missed estimates due to tariff refunds. Management cited strong sequencing consumables sales and NovaSeq X instrument placements. The broader market also fell, with AI-related stocks underperforming.

$ILMNHighAI 8/10

[Illumina Q3 2026 Earnings Call] Illumina Raises Full-Year Guidance to $4.64–$4.66 Billion as NovaSeq X Placements Top 80 and EPS Hits $1.44

Illumina reported Q3 2026 revenue of $1.17B, up 4.7% YoY, and EPS of $1.44. The company raised full-year guidance to $4.64–$4.66B, citing strong clinical demand and NovaSeq X placements. Operating margin was 25%, 100 bps ahead of guidance. Illumina expects 4.5% organic growth in Q4 and high-single-digit growth for 2027.